These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 15758718)

  • 1. Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml.
    Kundu SD; Grubb RL; Roehl KA; Antenor JA; Han M; Catalona WJ
    J Urol; 2005 Apr; 173(4):1116-20. PubMed ID: 15758718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
    Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
    JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.
    Catalona WJ; Smith DS; Ratliff TL; Basler JW
    JAMA; 1993 Aug; 270(8):948-54. PubMed ID: 7688438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.
    Krumholtz JS; Carvalhal GF; Ramos CG; Smith DS; Thorson P; Yan Y; Humphrey PA; Roehl KA; Catalona WJ
    Urology; 2002 Sep; 60(3):469-73; discussion 473-4. PubMed ID: 12350486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer screening in the Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur J Cancer; 2000 Jun; 36(10):1322-35. PubMed ID: 10882875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.
    Mettlin C; Murphy GP; Lee F; Littrup PJ; Chesley A; Babaian R; Badalament R; Kane RA; Mostofi FK
    Cancer; 1993 Sep; 72(5):1701-8. PubMed ID: 7688658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer.
    Halpern JA; Oromendia C; Shoag JE; Mittal S; Cosiano MF; Ballman KV; Vickers AJ; Hu JC
    J Urol; 2018 Apr; 199(4):947-953. PubMed ID: 29061540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
    Catalona WJ; Smith DS; Ornstein DK
    JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
    Schröder FH; van der Maas P; Beemsterboer P; Kruger AB; Hoedemaeker R; Rietbergen J; Kranse R
    J Natl Cancer Inst; 1998 Dec; 90(23):1817-23. PubMed ID: 9839522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer detection at low prostate specific antigen.
    Schröder FH; van der Cruijsen-Koeter I; de Koning HJ; Vis AN; Hoedemaeker RF; Kranse R
    J Urol; 2000 Mar; 163(3):806-12. PubMed ID: 10687982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).
    Vis AN; Hoedemaeker RF; Roobol M; van der Kwast TH; Schröder FH
    Prostate; 2001 Jun; 47(4):252-61. PubMed ID: 11398172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.
    Partin AW; Criley SR; Subong EN; Zincke H; Walsh PC; Oesterling JE
    J Urol; 1996 Apr; 155(4):1336-9. PubMed ID: 8632568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
    Dell'Atti L
    J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of compliance with prostate cancer screening guidelines.
    Grubb RL; Roehl KA; Antenor JA; Catalona WJ
    J Urol; 2005 Aug; 174(2):668-72; discussion 672. PubMed ID: 16006944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
    Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG; Pileblad E
    J Urol; 2003 May; 169(5):1720-3. PubMed ID: 12686817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Usefulness of screening for prostate cancer with prostate specific antigen (PSA) in the medical checkup ("human dock") at Onomichi Municipal Hospital: clinical significance of the cases diagnosed as prostate cancer].
    Oeda T; Kusumi N; Takamoto A
    Nihon Hinyokika Gakkai Zasshi; 2010 Jan; 101(1):18-24. PubMed ID: 20158074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.